{"id":"W4403563661","doi":"10.1016/j.ejca.2024.115078","title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Foundation Medicine; Chugai Pharmaceutical; Genentech; MacroGenics; Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Astellas Pharma; Eisai; Seagen; GlaxoSmithKline; UroGen Pharma; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; Clovis Oncology; Boston Scientific Corporation; AstraZeneca; Invitae; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Sanofi; Exelixis; Amgen; Myriad Genetics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Oncology; Internal medicine; Cancer; Urology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004004793,0.0007013836,0.001209133,0.0004000943,0.0002390706,0.000612327,0.0004765661,0.0004576761,0.002406846],"category_scores_gemma":[0.002751251,0.0002333284,0.001740863,0.0004739031,0.0003621586,0.0003701169,0.0002708412,0.0009449993,0.0002231056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004895281,"about_ca_system_score_gemma":0.001037232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004745988,"about_ca_topic_score_gemma":0.001744716,"domain_scores_codex":[0.9986522,0.000820614,0.00008844883,0.0001270224,0.0002299272,0.00008186939],"domain_scores_gemma":[0.9979506,0.0006007364,0.0008421789,0.0001558254,0.0002103959,0.000240292],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8411052,0.006048185,0.02961906,0.0022628,0.01392157,0.000215649,0.0001698207,0.002433265,0.01970986,0.0003066471,0.003533265,0.08067463],"study_design_scores_gemma":[0.6879498,0.172799,0.1117161,0.0001901995,0.01275651,0.0006292493,0.00009064306,0.001798584,0.005665372,0.0005238531,0.005808836,0.00007198864],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9846483,0.007935788,0.0009480817,0.0003941805,0.0000626994,0.001346392,0.002462065,0.00007098014,0.002131625],"genre_scores_gemma":[0.9919518,0.002827946,0.0007940405,0.0004809795,0.0001385488,0.0007090697,0.002591152,0.00001398779,0.0004924769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004004793,"threshold_uncertainty_score":0.02117962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.055486289193787,"score_gpt":0.4074318813970119,"score_spread":0.3519455922032249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}